Abstract:Objective: We aimed to explore the diagnostic and therapeutic efficacy of cystoscopy with hydrodistension and random biopsies for clinically suspected interstitial cystitis/bladder pain syndrome (IC/BPS). Study design: We reviewed the data of fifty-five clinically suspected IC/BPS patients underwent cystoscopy with hydrodistension and random biopsies. Global Response Assessment was used to evaluate the efficacy. Disease severity was assessed by thorough history, physical examination, 3-day frequency volume chart, visual analog scale of pain, Interstitial Cystitis Symptom Index (ICSI) and clinical phenotype system (UPOINT). Results: According to the pathologic outcomes from random biopsies, three out of the 55 clinically suspected IC/BPS were diagnosed as bladder carcinoma. Among the 52 IC/BPS patients, thirty-six patients (69.2%) had initial chief complaints of urinary frequency and urgency. Under cystoscopy, twenty-nine patients and 23 patients were classified as Hunner ulcer type and diffuse global mucosal bleeding (grade III glomerulation). The median functional bladder capacity of the 52 IC/BPS patients was 100 ml. Hydrodistension was effective in 28 patients (53.8%) at postoperative 3 months, which decreased to 25% at post-hydrodistension 6 months and to 13.5% at 12 months. For the 28 hydrodistensioneffective patients, the remission degrees of daytime frequency, nocturia, VAS bladder pain and ICSI score were 50.3%, 49.4%, 68.1% and 48%, which were significantly higher than the 16.9% (daytime frequency, P < 0.001), 20.5% (nocturia, P = 0.021), 7.4% (VAS pain score, P < 0.001) and 6.1% (ICSI, P < 0.001) in the hydrodistension-negative group. According to the UPOINT system, the hydrodistension-effective cases had significantly higher rates of symptom remission in U (P = 0.002), P (P = 0.026), O (P < 0.001), and T (P < 0.001) domains than the corresponding negative cases. In effective group, the O domain had the most remission rate (26 out of 28, 92.9%, P < 0.001), followed by the U domain (12 out of 28, 42.9%, P < 0.001) and T domain (12 out of 28, 42.9%, P < 0.001). Conclusion: Histopathological analysis from random biopsies could distinguish bladder carcinoma from clinically suspected IC/BPS. Hydrodistension is more likely to be effective when chronic pelvic pain is obviously alleviated. The efficacy of hydrodistension could act in a certain period of time. (c) 2021 Published by Elsevier B.V.

Multimodal Single‐Cell Analyses Outline the Immune Microenvironment and Therapeutic Effectors of Interstitial Cystitis/Bladder Pain Syndrome

Multi‐omics analyses uncover metabolic signatures and gene expression profiles of interstitial cystitis/bladder pain syndrome

Immunogenic Cell Death Associated Molecular Patterns and the Dual Role of IL17RA in Interstitial Cystitis/Bladder Pain Syndrome

Integrating single-cell RNA sequencing with spatial transcriptomics reveals immune landscape for interstitial cystitis

The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome

Identification of Immune-Related Genes and Small-Molecule Drugs in Interstitial Cystitis/Bladder Pain Syndrome Based on the Integrative Machine Learning Algorithms and Molecular Docking

Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome

A Shared B-cell Clonotype in Patients with Interstitial Cystitis/Bladder Pain Syndrome Presenting with Hunner Lesions

Identification of Key Genes in Human Urothelial Cells Corresponding to Interstitial Cystitis/bladder Pain Syndrome in a Lipopolysaccharide-Induced Cystitis Model.

PACAP/PAC1 Regulation in Cystitis Rats: Induction of Bladder Inflammation Cascade Leading to Bladder Dysfunction

Artesunate Remarkably Alleviates Interstitial Cystitis/bladder Pain Syndrome in a Murine Model: Novel Molecular Signature Deciphered by Bulk Tissue and Single-Cell Transcriptomic Analysis.

Promising Experimental Treatment in Animal Models and Human Studies of Interstitial Cystitis/Bladder Pain Syndrome

Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression

Expression of Programmed Death Ligand-1 on Bladder Tissues is Detected in a Clinically and Histologically Well-Defined Interstitial Cystitis Cohort.

Potential Urine and Serum Biomarkers in Patients with Bladder Pain Syndrome/Interstitial Cystitis

Identification of Circrna-Mirna-mrna Network As Biomarkers for Interstitial Cystitis/bladder Pain Syndrome.

Integrated Analysis of Microarray Studies to Identify Novel Diagnostic Markers in Bladder Pain Syndrome/Interstitial Cystitis with Hunner Lesion

The Diagnostic and Therapeutic Efficacy of Cystoscopy with Hydrodistension and Random Biopsies in Clinically Suspected Interstitial Cystitis/bladder Pain Syndrome.

Interstitial Cystitis/Bladder Pain Syndrome: a Review and an Update

Analysis of Key Genes and Micro-Rna-mrna Regulatory Networks in Women with Ulcerative Interstitial Cystitis/pain Bladder Syndrome

Stem cell therapy for interstitial cystitis/bladder pain syndrome